RepliCel Life Sciences Inc. announced that the dispute between Shiseido and RepliCel has led to the Company electing to terminate the license agreement with Shiseido. The company's decision is a legal step in its pursuit of a resolution of its disagreement with Shiseido that is the subject of ongoing arbitration proceedings under the aegis of the International Center for Dispute Resolution (ICDR). The dispute between Shiseido and RepliCel is related to a license for Asia to RepliCel's cell therapy technology for androgenetic alopecia, which is the leading cause of male and female pattern hair loss. Legal counsel for RepliCel filed a Notice of Arbitration that was announced in a Company press release on October 18, 2021.